Publications by authors named "Yein Jeon"
Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are FDA- and EMAapproved chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory large B-cell lymphoma (LBCL). However, comparative real-world analyses of their efficacy and toxicity with extended follow-up are lacking. We conducted a retrospective study of 160 LBCL patients treated at the Fred Hutchinson Cancer Center with commercial liso-cel or axi-cel per standard of care.
View Article and Find Full Text PDFArticle Synopsis
- - Immune effector cell-associated hematotoxicity (ICAHT) significantly affects patients undergoing CAR T-cell therapy, and the factors linked to severe forms of it are not well understood.
- - Researchers identified key pre-infusion and post-infusion factors that predict early severe ICAHT in a study involving 691 patients; these included disease type, blood counts, inflammatory and coagulopathy markers.
- - Two predictive models (eIPMPre and eIPMPost) were developed and validated, showing strong accuracy in predicting severe ICAHT, with the post-infusion model being particularly effective; an online tool for individualized predictions is available for use.
Background: The presence and interpretation of racial and ethnic differences in circulating N-terminal pro-brain-type natriuretic peptide (NT-proBNP), a diagnostic biomarker for heart failure, are controversial.
Objective: To examine racial and ethnic differences in NT-proBNP levels among the general US adult population.
Methods: We performed a cross-sectional analysis of data from the 1999-2004 National Health and Nutrition Examination Survey (NHANES).
Aims: Data on the long-term consequences of diabetic foot disease (DFD) are scarce. We examined the association between DFD and major clinical outcomes in patients with diabetes in the general population.
Methods: We conducted a prospective cohort analysis of 1,428 participants with diabetes in the Atherosclerosis Risk in Communities Study.